Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY22.90 CNY
Change Today -2.49 / -9.81%
Volume 10.1M
As of 3:00 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by HANGZHOU TIGERMED CONSULTI-A (300347) in the last 6 months

Announced 06/8/15
32.24B for DreamCIS, Inc.
Merger/Acquisition

Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) signed letter of intent to acquire 70% stake in DreamCIS, Inc. from Leenos Corp. (KOSDAQ:A039980) for KRW 27 billion on June 6, 2015. A total of 0.07 shares will be acquired as part of this transaction. Expected closing is on October 12, 2015. Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) agreed to acquire 98.14% stake in DreamCIS, Inc. from Leenos Corp. (KOSDAQ:A039980) and Won-Young Choi for KRW 32.2 billion ...
Read More


300347's price was unchanged after the transaction was announced on 06/8/15.
Investor / Buyer
Hangzhou Tigermed Consulting Co., Ltd.
Creditor / Lender
Leenos Corp.
 
Announced 04/8/15
Taizhou Jietong Tairui Pharmaceutical Technology Co., Ltd.
Merger/Acquisition

Walvax Biotechnology Co.,Ltd (SZSE:300142), Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347), Sinkiang-based equity investment company and other investors signed an equity acquisition agreement to acquire a 54% stake in Taizhou Jietong Tairui Pharmaceutical Technology Co., Ltd. from Xinjiang Tairui Equity Investment Partnership, Fu Xiaoyang and another individual on April 8, 2015. The acquisition will be made through a newly established fund with a registration capital ...
Read More


300347's price was unchanged after the transaction was announced on 04/8/15.
Investor / Buyer
Hangzhou Tigermed Consulting Co., Ltd.
Walvax Biotechnology Co.,Ltd
Creditor / Lender
Xinjiang Tairui Equity Investment Partnership
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300347:CH CNY22.90 CNY -2.49

300347 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
PAREXEL International Corp $64.09 USD -0.46
WuXi PharmaTech Cayman Inc $42.37 USD +0.05
View Industry Companies
 

Industry Analysis

300347

Industry Average

Valuation 300347 Industry Range
Price/Earnings 64.8x
Price/Sales 11.9x
Price/Book 10.8x
Price/Cash Flow 65.4x
TEV/Sales 11.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANGZHOU TIGERMED CONSULTI-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.